Access to Tirzepatide (Mounjaro®) for Weight Management in the Black Country
Black Country ICB are commissioning tirzepatide (Mounjaro®) for the management of obesity for an eligible cohort of people who meet the following criteria.
- Have a BMI of 40 or more (or 37.5 for people from minority ethnic backgrounds),
- And have obstructive sleep apnoea on CPAP (or where CPAP is not tolerated)
And have at least three of the following long-term conditions:
- Type 2 diabetes
- High blood pressure (hypertension)
- Cardiovascular disease
- Dyslipidaemia
This is in line with NHS England’s interim national commissioning guidance for the implementation of NICE TA1026.
If you have previously accessed tirzepatide through a private provider, the NHS may only continue treatment if you meet the current NHS eligibility criteria following an assessment by the Integrated Care Board’s commissioned weight management service.
If you do not meet the current eligibility criteria in the Black Country, you will be advised of this. Whilst we recognise this may be disappointing, it's important to note there are other NHS services that can support you. These may include:
- Tier 2 weight management programmes
- Dietitian referrals
- Digital tools and lifestyle coaching
Please be aware if you contact an NHS service with questions about your private tirzepatide prescription, including stopping or tapering off the drug, you be advised to speak with your private provider.
Please note:
Access to tirzepatide will be alongside structured diet, exercise and behavioural support to ensure patients are supported in achieving and maintaining a healthy weight.
The ICB website has the latest ICB policy and FAQs for weight management published by NHS England, which may give you more information.
